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Leptospirosis is a zoonotic spirochaetal illness that is endemic in many tropical countries. The research base on
leptospirosis is not as strong as other tropical infections such as malaria. However, it is a lethal infection that can
attack many vital organs in its severe form, leading to multi-organ dysfunction syndrome and death. There are
many gaps in knowledge regarding the pathophysiology of leptospirosis and the role of host immunity in causing
symptoms. This hinders essential steps in combating disease, such as developing a potential vaccine. Another major
problem with leptospirosis is the lack of an easy to perform, accurate diagnostic tests. Many clinicians in resource
limited settings resort to clinical judgment in diagnosing leptospirosis. This is unfortunate, as many other diseases
such as dengue, hanta virus, rickettsial infections, and even severe bacterial sepsis, can mimic leptospirosis. Another
interesting problem is the prediction of disease severity at the onset of the illness. The majority of patients recover
from leptospirosis with only a mild febrile illness, while a few others have severe illness with multi-organ failure.
Clinical features are poor predictors of potential severity of infection, and therefore the search is on for potential
biomarkers that can serve as early warnings for severe disease. This review concentrates on these three important
aspects of this neglected tropical disease: diagnostics, developing a vaccine, and potential biomarkers to predict
disease severity.
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Leptospirosis is a zoonotic disease caused by spirochaetes
of the genus Leptospira. The disease results in high mor-
bidity and considerable mortality in areas of high preva-
lence [1]. It is estimated that around 10,000 cases of severe
leptospirosis are hospitalized annually worldwide [2]. The
disease is endemic in areas with high rainfall, close human
contact with livestock, poor sanitation and workplace
exposure to the organism [3]. There are currently 14 iden-
tified potentially pathogenic species of leptospira (9 definite
and 5 intermediate). Any mammal has the potential to be
the reservoir for the organism, but it is predominantly
rodents who play a role in transmitting infection to
humans. The organisms can be transferred to humans
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unless otherwise stated.animals, with entry of the organisms occurring through
mucosal surfaces or breached skin [2].
Primarily manifesting as an acute febrile illness, severe
forms of leptospirosis affect multiple organ systems,
resulting in acute kidney injury, pulmonary haemorrhage,
hepatitis, myocarditis, disseminated intravascular coagula-
tion, and meningo-encephalitis. The case fatality rate in
severe leptospirosis can exceed 40% [4]. It is postulated
that severe disease is driven largely by the host immuno-
logical response rather than the pathogen’s virulence.
There are a multitude of unresolved, practically relevant
areas on this illness that need to be addressed by further
research. In this review, we focus on three important
areas, i.e., diagnostics, vaccine development, and identifi-
cation of biomarkers of disease severity.Methods
A MEDLINE search was performed for articles with the
keywords ‘leptospirosis’ OR ‘leptospira’ OR ‘Weil’s’ ORral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cles published in English within the last 15 years (1998 –
September 2013) as they would contain more recent data.
The search was also restricted to studies reporting on
humans (not animals). There were 1442 abstracts in the
original search with these restrictions. The software End-
note X3 was used to filter articles. Bibliographies of cited
literature were also searched. All abstracts were read
through independently by the three authors, and relevant
papers were identified for review of the full papers.
Related papers were also included. We reviewed 159
selected full papers.
These sources were screened for a well described meth-
odology, accurate statistical analysis and an adequate sam-
ple size where relevant. Data sources included reviews
published in core clinical journals, cohort studies, interven-
tional studies, case control studies, cross sectional analysis
and epidemiological data. Suitable data was available in 49
papers from the initially selected 159.
Leptospirosis: diagnostic issues
Laboratory diagnosis of leptospirosis remains a challenge.
There are many diagnostic tests for leptospirosis. These
can be broadly divided according to their methodology
into: a) methods demonstrating the organism in culture or
clinical specimens, b) immunological methods, and c)
genomic methods.
Direct demonstration of organisms
The simplest diagnostic procedure is demonstrating the
organism in urine or blood with dark ground microscopy
(DGM). However, the sensitivity and specificity is question-
able, despite the low cost. In addition, ideal diagnostic
conditions with DGM require the specimen to be prepared
from culture, which is very difficult to achieve since the
organism is fastidious. Chandrasekaran et al. [5] compared
the usefulness of DGM vs. IgM ELISA, and concluded that
DGM had high positivity in patients with clinically sus-
pected leptospirosis compared to ELISA (95.5% vs. 64.7%).
The positivity of DGM diminished, and that of ELISA in-
creased (though still DGM had higher positivity) with the
duration of infection. Comparison was not made against a
gold standard in this case, and the study simply compared
positivity with the two tests in clinically suspected cases. In
another study of 297 samples, sensitivity and specificity of
DGM was around 60% [6].
Immunological diagnostics
The immunological reference standard for diagnosis of
leptospirosis is the microscopic agglutination test (MAT).
However, this test involves the cumbersome procedure of
reacting the patient’s serum with different panels of live
leptospira antigens. MAT is not specific for IgM, and
detects both IgM and IgG, and may not be able todifferentiate acute from previous infection. Furthermore,
there is little evidence on how long IgG antibodies persist
in blood after acute infection. Thus ideally, the test
requires two samples (acute and convalescent) for confirm-
ation. In a clinical setting where rapid decision making is
necessary, MAT is not be the ideal test to go by for
diagnostic confirmation.
Other immunological tests available include IgM ELISA,
microcapsule agglutination test, Lepto-dipstick, Lepto Dri
Dot, and Leptocheck-WB test. These allow rapid diagno-
sis, and are simpler to perform than MAT. Still, all these
tests can be negative in early leptospirosis as it takes time
for antibodies to form. The sensitivities and specificities of
the tests vary depending on the antibodies present and the
leptospira antigen used. For example Boonyod and col-
leagues [7] demonstrated that a rapid diagnostic test using
a dipstick for the outer membrane protein (OMP) LipL32,
which is expressed in pathogenic leptospira, had good
sensitivity and specificity to MAT (100% and 98.3%
respectively). The suitability of this antigen for pathogenic
leptospira diagnosis has been independently confirmed by
others [8-10]. A group of investigators in Brazil assessed
the use of Leptospira immunoglobulin (Lig)-like proteins
as antigens to react with IgM antibodies in patient’s sera
in an immunoblot assay. This had a sensitivity of 81%
during the first 7 days of illness. Neves and colleagues [11]
identified two proteins, namely Lp29 and Lp49, which
were reactive with sera of patients during an outbreak in
Brazil. These proteins were identified after screening the
L. interrogans genome for potential sequences that code
for outer membrane proteins. The IgM for these proteins
were detected in sera of patients in both acute and conva-
lescent phases, and IgM against Lp29 was detected when
the MAT was negative in the acute phase of illness. How-
ever, it was not confirmed whether these proteins were
present in all pathogenic serovars of leptospirosis. An IgM
immunoblot test against antigens of several leptospira
serovars prevalent in Thailand yielded positive results,
with a sensitivity of 88% during the first three days since
onset of symptoms (corresponding MAT sensitivity in this
early sample was just 2%). ELISA assays based on recom-
binant products of OMPs are developed for locally circu-
lating virulent organisms. Whether they would be useful
outside a particular geographical area is doubtful. In a
large scale study in Andaman Islands, researchers devel-
oped an IgM ELISA study for two OMPs (OmpL1 and
LipL41) of locally prevalent virulent leptospira serovars
that caused severe pulmonary leptospirosis [12]. The test
had sensitivities and specificities ranging between 80-90%
compared against MAT but may not be universally applic-
able for different serovars that are prevalent in other areas.
Senthilkumar et al. [13], in an attempt to develop a rapid
diagnostic method, assessed recombinant LipL41 protein
as an antigen to be used in latex agglutination test (LAT)
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among all pathogenic species of leptospirosis. Both tests
took less than 5 minutes to complete and had good sensi-
tivities and specificities when compared against MAT
(sensitivity and specificity 89.7% and 90.4% respectively
for LAT, 77% and 89% for flow through assay). Other
recombinant conserved proteins of pathogenic leptos-
pira that have yielded good results in immunological
diagnostics include: rligA [14], Hap1/lipL32 [15], and
rLoa22 [16].
Another interesting aspect to leptospirosis diagnosis by
immunological methods was adopted by Lin et al. [17].
They considered five immunodominant epitopes of three
OMPs of pathogenic leptospira (OmpL1, LipL21, and
LipL32) and constructed a synthetic gene (rlmp). The
purified protein product of this gene was used as an anti-
gen to react with patient sera (with both IgM and IgG
antibodies) of confirmed leptospirosis patients in an
ELISA test. The results were encouraging with no cross
reactions and false positives in control groups, and detect-
ing all MAT positive leptospirosis with the new test. In a
similar experiment, Sun et al. [18] created a recombinant
fusion protein of the same antigens that was later used in
an IgM ELISA for early diagnosis of leptospirosis. The
ELISA with the recombinant protein yielded better results
(>95% sensitivity in a sample of 493 leptospirosis patients)
than ELISA tests using each of the individual antigens.
Additionally they demonstrated that this antigen did not
cross react with sera of patients with non-leptospirosis
fevers, such as dengue and typhus.
Finally, a recently published meta-analysis of ELISA
diagnostic tests for leptospirosis holds that they have a
fairly good sensitivity and specificity (77% and 91%
respectively; area under the curve 0.964). The drawbacks
were the heterogeneity among the tests and the lower
yield in the initial phase of the illness [19]. This remains
the main problem with IgM ELISA tests for leptospirosis,
i.e., heterogeneity between different antigens used for
testing essentially affects sensitivity among different
strains of the organism.
While being less sophisticated and time consuming than
the MAT, ELISA tests also need considerable laboratory
support. Rapid diagnostic tests (RDT) are an alternative
for on-field diagnosis with minimal laboratory support.
Goris and colleagues [20] evaluated three commercially
available RDTs (LeptoTek Dri Dot, LeptoTek Lateral Flow,
and Leptocheck-WB) against the MAT and ELISA test
results for the same samples. All three tests had sensitivity
of more than 75% and specificity of at least 95%. However
in order to obtain a better sensitivity, at least two samples
had to be tested per patient (sensitivity for single samples
ranged from 51-69%). It was concluded that RDTs alone
cannot be relied upon to diagnose leptospirosis, especially
in the earlier stages of the illness.However, all these comparisons of different immuno-
logical diagnostic tests need a gold standard for a valid
comparison. Until recently this gold standard was MAT
(or culture which has low sensitivity as the organism is
fastidious). Unfortunately, the MAT is in itself an imper-
fect gold standard, which makes the sensitivities and spec-
ificities of other tests judged against it less reliable and
hence has to be interpreted with caution (see below) [21].
Genomic diagnostics
Genomic diagnostic tests have the advantage of being
positive early in disease, but have the disadvantages of lim-
ited availability and high cost. There are several diagnostic
techniques that can be employed in the genomic diagno-
sis. These are outlined below.
Polymerase chain reaction (PCR): Involves amplifying
DNA sequences specific to the organism, using primers.
Provided the sequence amplified is specific to the patho-
gen, this method has the potential to be 100% specific.
Gravekamp et al. [22] developed two groups of primers
(G1 & G2 and B64 I & B64 II) that were capable of diag-
nosing all genospecies of leptospira known upto the year
2003, and these had been used heavily in studies that re-
quired specific diagnosis of leptospirosis. De Abreu Fon-
seca et al. [23] compared the sensitivity and specificity of
PCR against that of MAT and IgM ELISA in 124 serum
samples (60 with confirmed leptospirosis). The specificity
of PCR was 100% but the sensitivity varied between
44-62% with less sensitivity for samples collected later on
in the infection. The sensitivities for MAT ranged between
69 -95% and increased with duration since infection (spe-
cificity of MAT ranged between 90 – 100%). Combination
of PCR and ELISA increased the sensitivity to 93-95%
during first week of infection. Similar findings have been
demonstrated by other authors as well [24].
Arbitrarily primed PCR: This technique uses an arbi-
trary primer to amplify segments of DNA which on gel
electrophoresis should produce a specific pattern of bands
that is species specific. However, even within the same
species, researchers have shown that arbitrary primed
DNA banding patterns can differ.
Nucleic acid probes: This is a very specific technique
that allows diagnosis of infection at a very early stage.
Provided the probe is a specific one, it will enable species
differentiation.
Restriction enzyme analysis (REA): Cleaving purified
dsDNA of leptospira by restriction enzymes gives a spe-
cific DNA fingerprint when run on gel electrophoresis.
Recognizing this pattern will enable to identify members
of same species with same restriction sites. While this can
be used as a diagnostic technique, application of this has
also enabled to further genetically classify subspecies or
identify new species that were previously thought to be a
single species.
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(RAPD): This involves combination of arbitrary primer
use and PCR to generate a unique pattern of genomic
bands that is specific at species level. This technique has
enabled rapid differentiation between different species but
has the disadvantage of needing pure cultures to extract
DNA.
Pulsed field gel electrophoresis: This is a technically
cumbersome procedure of generating larger genomic frag-
ments by restriction enzymes that need to be moved and
separated by a special gel electrophoresis. While being a
difficult process, it allows a relatively reproducible frac-
tionation of an entire bacterial genome on a single gel.
Ribotyping: Ribosomal RNA (rRNA) is relatively well
conserved within the species. Bacteriologists use probes
on rRNA to identify the phylogenetic position of bacteria.
It has been suggested that this tool may be useful in
identifying the epidemiology and species differentiation of
leptospira. Taking MAT/culture as the gold standard,
Thaipadungpanit et al. [25] compared the diagnostic spe-
cificity and sensitivity of detection of genomic 16 s rRNA
and lipL32 gene in 133 cases of leptospirosis (plus 133
controls). The diagnostic sensitivity was low with both
tests, but was better in the 16 s rRNA assay (53 vs. 46%);
specificity was high, but lower with 16 s rRNA (90 vs.
93%). The advantage of these tests compared to MAT is
that detection of genomic material can be done at a very
early stage of the illness without having to wait for anti-
body development. In Sri Lanka, Agampodi et al. [26]
used quantitative PCR to amplify 16 s rRNA, and found
that sensitivity was much better when serum was used as
the source than whole blood (51 vs 18%). Quantitative
leptospiraemia correlated with myocarditis, renal failure
and multi organ failure. Furthermore, sensitivity of PCR
was not affected by the duration of illness.
DNA sequencing: Sequencing nucleic acids at a particu-
lar genetic locus allows to identify interspecies differences
and genetically classify different serovars. This is a labori-
ous and expensive technique.
In an overall analysis of diagnostic tests for leptospirosis,
the trend now is to find a test that will yield good results as
early as possible in the disease process. Culture and MAT,
though considered to be the gold standard, are clearly un-
suitable in this regard as they are cumbersome and time
consuming. Of the serological tests, several studies have in-
dicated the possibility of utilizing antibodies against OMPs
of pathogenic leptospira species for early diagnosis with
good sensitivity and specificity. Most of these tests utilize
IgM antibodies though some utilize IgG antibodies. How-
ever, the disadvantage is that the antigen against which the
antibodies are developed may not be conserved among all
pathogenic leptospirosis serovars. If that is the case then
tests developed for circulating serovars in one locality may
not be applicable to others. However, many proteins thathave been mentioned above seem to be conserved across
the pathogenic species. MAT, despite being the “gold
standard” has its own problems. It requires the continuous
maintenance of live leptospira antigens in a panel of differ-
ent serovars. If the standard panel does not contain a lo-
cally prevalent serovar, again the diagnosis may be missed.
In most previous studies of new diagnostic tests, com-
parison has been made with MAT as the reference stand-
ard. The validity of comparing new immunodiagnostics
with MAT as the “gold standard” has been debated [21],
for the reasons mentioned earlier. Bayesian latent class
modeling has been suggested over traditional gold stand-
ard analysis when evaluating new immunological diagnos-
tic tests. The role of genetic testing has come to the fore
recently mainly because of better sensitivity in early
disease compared to MAT. Theoretically, genomic antigen
detection would allow better and faster diagnosis, but
these methods are not widely available, and are likely to
be costly.
Developing a vaccine for leptospirosis
There is currently no widely used vaccine for leptospirosis.
The first vaccine introduced for leptospirosis was a killed
whole cell vaccine that consisted of formalin-killed lepto-
spires [27]. Various studies report the duration of efficacy
of whole cell vaccines to be between 6 months to 7 years.
However, in most studies, the duration of protection was
at best 3 years [27]. The problem with this vaccine is that
its serovar specific [27]. The monovalent vaccine did not
protect against infection by other serovars and therefore
its protection is dependent on the locally isolated serovars.
This fact, plus its side effects, has led to other options
being explored in vaccine designing.
Leptospiral lipopolysacharides (LPS) are an area of inter-
est for vaccine developers. However, immunity generated
by these antigens was also considered to be serovar spe-
cific. Some success with LPS vaccines has been demon-
strated in animal models.
Protein antigens are a mainstay of the current drive to
develop a leptospirosis vaccine. The discovery of outer
membrane proteins of leptospira that were common or
conserved in pathogenic species has generated interest
among immunologists and vaccinologists in developing
a polyvalent vaccine that is effective against different
pathogenic species with minimum side effects. Subunit
vaccines cause less side effects than whole cell vaccines.
The proteins of interest are: Omp L1 (transmembrane
protein), LipL41 (outer membrane protein), LipL32/
Hap-1, Leptospiral immunoglobulin-like proteins [28]
and LemA [29]. Seixas and colleagues [30] evaluated the
potential of using LipL32 with various vaccine platforms
to induce immunity in an animal model (rBCG vaccine,
DNA vaccine and a subunit vaccine). The protein was
immunogenic and the subunit vaccine gave the highest
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LipL32 inhibited leptospira growth in vitro.
The leptospiral immunoglobulin-like proteins consist of
three proteins LigA, LigB and LigC. LigA and B have been
to shown to have immunogenic potential in animal
models [31]. LigB is universally present in all pathogenic
leptospira serovars and therefore carries the best hope for
being an immunogenic component in a recombinant uni-
versal leptospirosis vaccine [32]. Cao and colleagues [33]
developed a fusion recombinant protein of two immuno-
genic proteins (immunoglobulin like proteins and LipL32)
and the combined product (in various combinations) had
good protective efficacy in a hamster model. The authors
also noted that using LipL32 alone was not as successful
as using the combined protein. However in a subsequent
paper, a different group of investigators reported that
when LipL32 is combined with B subunit of E. coli heat
liable enterotoxin, it evoked a significant immunoprotec-
tive effect [34].
With sequencing of entire genomes of some patho-
genic leptospira species, the possibility of isolating se-
quences that might code for membrane proteins that are
potential candidates for vaccine development has
opened up. Such areas can be recognized by scanning
the entire genome with computer generated algorithms;
identified genes can be cloned and their proteins puri-
fied to check for antigenicity [35-37]. This is a very com-
plex process, but has immense potential for future
vaccine development. Such putative protein products
have been purified and tried in animal models with some
promising results.
Overall, despite the advances in biotechnology, the
only usable efficacious vaccine for leptospirosis to date
are the whole cell inactivated vaccines. Vaccines based
on recombinant membrane proteins have only been tried
out in animals with limited success. The disadvantage of
whole cell vaccines is that they are serovar specific (poly-
valent vaccines can be made by using several serovars in
one vaccine) and therefore can be used in a geographic-
ally restricted area. Nonetheless, given the limited pro-
gression on developing a universally useful vaccine
active against all pathogenic serovars, the most cost ef-
fective measure for a developing country is to work on a
locally effective killed whole cell vaccine.
Molecular markers of severe leptospirosis
Leptospirosis is a disease with a wide spectrum of mani-
festations. Only a minority of infected people will de-
velop severe disease with multi-organ failure. This
severe disease is seen with certain serovars but not all
individuals infected with a particular serovar will develop
severe disease. To make matters complex, the classifica-
tion of serovars is a cumbersome process that is
dependent on detailed immunological phenotyping. Itdoes not relate with leptospira species categorization
which is based on DNA analysis. While serovar diagno-
sis is relatively freely available, DNA based species
categorization is only available in reference genetic la-
boratories. This creates a barrier in correlating clinical
features with the infecting species.
Why certain infections in some people lead to severe
disease, while others have a mild illness, is an unresolved
mystery. Current thinking is that both pathogen related
(infecting serovar/species, innoculum size) and host factors
(immunological response) contribute to this heterogeneity.
However, if certain markers of severe disease can be identi-
fied either in the host or the pathogen, it will be of great
help in predicting severe disease.
One particular compound that has been of interest in
this regard is nitric oxide. It is known that in a state of
inflammation, release of inflammatory cytokines (TNF-α,
IL-1,6) activate inducible nitric oxide synthatase (iNOS) to
produce NO which is bacteriostatic. NO is metabolized to
nitrite, which has a short half-life in blood, and then to ni-
trate. Estimation of NO activity can be made by measuring
nitrites, nitrates or both. There is limited evidence as to
which metabolite most accurately reflects NO activity in
response to severe infection. Nitrite is likely to be more
specific, as it has a short half life, and is less affected by
renal function. It was hypothesized that in severe lepto-
spirosis the level of NO may be elevated. This hypothesis
was confirmed by two separate studies six years apart,
where serum NO levels were shown to be raised in
patients with symptomatic leptospirosis [38,39]. However,
a paradox in serum nitrate concentrations (a surrogate
marker of NO) has been demonstrated in malaria where
people with severe malaria actually had paradoxically low
total NOx (nitrite and nitrate) levels when it was corrected
for serum creatinine. In severe leptospirosis, since there is
renal impairment, it is possible that the raised NO level
may not reflect increased synthetic activity but reduced
clearance of NO via the kidneys. In fact a recently pub-
lished paper by Kalugalage et al. [40] demonstrated that,
as in malaria, the corrected NO concentration (corrected
for renal impairment) in patients with severe leptospirosis
is actually lower than in non-leptospirosis fever patients
and patients with mild leptospirosis. The pathophysio-
logical basis for this phenomenon remains elusive.
Whether low NO levels contribute to pathogenesis of
severe disease or whether it is a result of severe disease
and acute kidney injury is unclear. Interestingly, there is
an animal study by Pretre et al. [41] where infected mice
and hamsters showed increased iNOS mRNA and protein
in kidneys compared to controls. Giving the animals
4-aminopyridine, which is a iNOS inhibitor, caused faster
deterioration. NO is one of the mediators which drives
oxidative stress, and, like in many other diseases, oxida-
tive stress is likely to play a role in tissue and organ
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this is limited.
Studies of immunochemical markers have shown that
both cell mediated as well as humoral immunity are
activated in severe leptospirosis. De Fost et al. [42], in an
analysis of 44 Thai patients with definite or suspected
leptospirosis, showed that markers of cell mediated im-
mune activity was raised compared to healthy controls
(Interferon [IFN]-gamma-inducible protein-10, granzyme
B, monokine induced by IFN-gamma).
Proteomics seem to be a promising tool to study the in-
flammatory response in acute leptospirosis. The genomic
sequences, despite being highly conserved among mem-
bers of a species, do not show the functional status of a
living cell (as genes are selectively turned on and off).
Study of mRNA, though theoretically better to analyze
gene expression, has many technical difficulties in practice
(they are rapidly degraded, and not all mRNA are trans-
lated to proteins). In the light of these findings, the best
way to assess the functional status of a cell is to assess its
protein profile. However assessment of such profiles is
complex, as these profiles change with time and from cell
to cell depending on gene activation. Mass scale analysis
of proteins in leptospirosis patients with severe disease
has enabled identification of proteins that are differentially
expressed in severe disease. Such identified proteins can
be targets for further studies on pathogenesis and vaccine
development [43,44]. In the most recently published study
on proteomic analysis of serum of leptospirosis patients
(compared to controls with malaria and healthy volun-
teers) Srivastava and colleagues [45] demonstrated several
differentially expressed proteins in leptospirosis patients
that were not previously associated with the disease
pathogenesis. Therefore this is a rapidly evolving field.
Whether certain hosts of a particular genetic makeup
have increased vulnerability to leptospirosis is of interest.
A study by Fialho et al. [46] compared victims of lepto-
spirosis with healthy controls for HLA alleles and genetic
polymorphisms in the cytokine genes. Significant associa-
tions were found for certain alleles of HLA-A,B loci plus
several HLA haplotypes. Polymorphisms in IL-4 and IL-
4Rα genes were also significantly associated with a past
history of leptospirosis. However, these findings have not
been confirmed in larger population samples. Other stud-
ies have assessed different mediators of sepsis and cyto-
kines in relation to severe leptospirosis. These mediators
include human serum mannose binding lectin (which
identifies pathogens activating the immune system) [47],
soluble ST2 receptors, long pentraxin PTX3, copeptin and
platelet activating factor acetylhydrolase (limited studies
in animal models).
Membrane bound ST2 (mST2) is a negative regulator of
toll like receptors (which is an important component of
innate immunity). sST2 (soluble ST2) inhibits signalingvia mST2. In an observational study in 68 severe leptospir-
osis patients, Wagenaar et al. [48] demonstrated that sST2
levels, cytokines IL-6, IL-8, and IL-10 were elevated in all
patients. However sST2 levels had a significant association
with any bleeding manifestation and severe bleeding. It
also had a significant association with mortality (OR 2.4;
95% CI: 1.0-5.8). Interleukins 6 and 8 also showed a sig-
nificant association with mortality but not with bleeding.
In another study of assessing biomarkers of clinically se-
vere leptospirosis, Wagenaar et al. [49] have shown that
PTX3, a long pentraxin (pentraxins are a super family of
large multimeric proteins that are thought play an import-
ant role in innate immunity and adjusting immune
response) was elevated in leptospirosis and showed a
significant association with mortality and disease severity.
C-reactive protein is a structurally related protein (short
pentraxin) but it did not show such a correlation with dis-
ease severity or death. In this study, both IL-6 and 8 were
also shown to have a significant association with mortality.
On the same cohort of patients, authors have also shown
that copeptin (a stable peptide of arginine vasopressin pre-
cursor that is released in increased amounts in sepsis)
levels were elevated in patients with severe leptospirosis
and elevated levels were significantly associated with high
mortality [50].
The study of biomarkers for severe disease has become
more complex with recent genome wide studies in leptos-
pira genome. Comparative analysis of saprophytic and
pathogenic leptospira has shown that nearly 900 genes in
pathogenic strains may be contributing to the patho-
genicity of disease [51]. The functions of most of these
genes are unknown and the known proteins which are
thought to be of functional significance cannot explain
all the virulence mechanisms of the organism. To make
matters more complicated, it has been demonstrated
that some of these genes are differentially regulated
depending on the ambient conditions (temperature,
osmolarity and iron levels). Mutation analysis systems
have shown that some genes have definite roles in
pathogenesis (as mutations in these genes attenuate
virulence) and these include OmpA-family protein, Loa
22 and several other proteins [51].
Identified areas for further research in this fast devel-
oping field are; a) serial measurement of NOx levels in
patients with leptospirosis to identify its use as a
predictor of severity, b) further analysis of NOx with
correction for creatinine released from muscle, c) further
exploration of the role of oxidative stress in tissue and
organ damage, d) use of cytokines as predictors of dis-
ease severity and e) proteomic analysis of sera of severe
leptospirosis, mild leptospirosis, non leptospirosis fever
patients (and healthy controls) on admission and serially
to identify differentially expressed proteins that can be
potential severity markers.
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The ideal diagnostic test for leptospirosis should give a
positive result as early as possible, should have good sensi-
tivity and specificity plus be cost effective. MAT which is
the presumed “gold standard” for leptospirosis is probably
unsuitable for routine diagnosis due to its high false nega-
tive readings in early disease, lack of specificity for acute
infection, and the cumbersomeness of the process. Other
immunological methods such as immunochromatography
and IgM ELISA have shown promise with early diagnosis
and good sensitivities and specificities compared to MAT.
Given the fact that MAT is may not be the ideal gold
standard, Bayesian latent class models have shown that
the sensitivities and specificities of these other tests may
be higher than expected. Genomic diagnostics offer an-
other exciting diagnostic possibility in early disease. How-
ever, the yields of these tests are low and they also need
expensive equipment that is not freely available. Their use
is currently limited to research and genotypic analysis.
The quest for a successful vaccine continues. The most
efficient vaccines to-date are the whole cell killed vaccines
which were also the earliest vaccines developed against
leptospirosis. The disadvantage of these are that they are
either monovalent or offers protection to a few locally
circulating serovars. Research on subunit vaccines which
offers universal protection against all pathogenic leptos-
pira have not shown promising results despite having
identified several proteins that are conserved among all
pathogenic leptospira identified to-date.
Clinical features are not very good predictors of poten-
tial disease severity and therefore much of the recent focus
in leptospirosis research is on identification of biomarkers
that will predict severe disease in patients. Immunological
studies have evaluated the role of cytokines such as IFN-γ,
IL-6 and IL-8 in leptospirosis. Non specific activation of
other cytokines such as TNF-α and IL-1 can increase the
oxidative stress and free radicals. These may induce nitric
oxide synthase activity resulting in higher total nitrite
levels and overall reduced antioxidant capacity. They may
have value as severity predictors. Genetic heterogeneity of
HLA alleles, cytokine genes and proteomics of host and
genomics of the pathogen are new ongoing avenues in re-
search that might shed light in to having robust predictors
for severe disease in future.
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